Skip to main content
Loading...
Menu social network
LinkedIn
Facebook
X
Youtube
Menu top
Assistance
User account menu
Log in
Main navigation
Home
Programme
Download the app
App
Download the app
App
Menu
Login
Close
Main navigation mobile
Home
Programme
Menu top
Assistance
Menu social network
LinkedIn
Facebook
X
Youtube
26 results
D2.380 - Incidental Low Serum IgE: A Marker of Underlying Inborn Errors of Immunity?
D2.383 - Ocular Cicatricial Pemphigoid: Experience with Methotrexate immunosuppression in a case series from Mar del Plata, Argentina
D2.389 - Optic disc swelling in Common variable immunodeficiency, two cases from a small U.K. cohort
D2.381 - Early Infantile Immune Dysregulation with an Atopic Phenotype: A Case of Genetically Confirmed Otulipenia
D2.382 - Contribution of Clinical and Laboratory Findings to Genetic Testing Decisions and Diagnostic Yield in Patients with Suspected Primary Immunodeficiency
D2.384 - Early inflammatory manifestations in a child carrying a heterozygous TREX1 variant: possible evolving interferonopathy?
D2.385 - Granulomatous and Lymphocytic Inerstitial Lung Disease (GLILD) in Common Variable Immunodeficiencies (CVIDs): preliminary results of a multicenter retrospective observational study
D2.386 - Intravenous Immunoglobulin–Associated Severe Prolonged Neutropenia: A Rare but Life-Threatening Complication in Primary Immunodeficiency
D2.387 - Hemophagocytic Lymphohistiocytosis and Progressive Neurological Involvement in Two Patients with Severe Congenital Neutropenia Due to VPS45 Deficiency
D2.388 - Is Sarcoidosis a preliminary feature of Inborn Errors of Immunity?
D2.390 - Evaluation of CD4⁻ CD8⁻ T Cell Population According to Patient Diagnostic Groups: A Single-Center Study
D2.391 - Assessment of Small Airway Dysfunction by Impulse Oscillometry in Patients with CVID and Selective IgA Deficiency
D1.105 - Real-Life Evidence of Type 2 Immunomodulation with Benralizumab: From Steroid-Dependent to Controlled Asthma
D1.106 - Dupilumab-Induced Systemic Eosinophilic Immune Activation Mimicking an EGPA-Like Prodrome: A Case Report
D1.108 - Optimization of phenotyping in severe T2-bronchial asthma
D1.109 - Biologics selection algorithm for severe T2-bronchial asthma targeted therapy
D1.110 - Long Term Mepolizumab in Type-2 CRSwNP: Marked Polyp Reduction, Symptom Relief, and Airway Benefits in Real World Comorbid Patients
D1.111 - Tezepelumab reduces in patients with severe allergic asthma and rhinoconjunctivitis not only bronchial but also nasal and conjunctival symptoms – results from an exposure chamber study
D1.112 - ILC2 Expansion as a Biomarker of Suboptimal Response to Dupilumab in Severe Asthma: Findings from the PRISM Study
D1.113 - Effect of mepolizumab in eosinophilic granulomatosis with polyangiitis (EGPA): a real-world retrospective observational study
Pagination
Current page
1
Page
2
Next page
Next
Last page
Last
Download the app
The congress at your fingertips
Available on
Download